Cue Biopharma (CUE) Stock
Early stage biotech developing cancer immune treatments. Here's the price, business snapshot, and what's worth knowing about Cue Biopharma in October 2026.
Cue BioPharma (ticker: CUE) is a clinical-stage biotechnology company developing targeted immune activators designed to engage a patient’s own immune system against cancer. Its technology seeks to direct and amplify antigen-specific T cell responses, with lead candidates in oncology indications. As an early-stage biopharma with a market capitalisation around $63.4m, Cue is research- and development‑intensive and typically reports limited or no commercial revenue. Key points for investors include the binary nature of clinical trial readouts, dependence on successful regulatory interactions, and the potential need for additional financing which can dilute shareholders. The share price can be volatile and sensitive to scientific data, partnership news and funding updates. For many investors, Cue may be better suited to a small, speculative part of a diversified portfolio. This is educational information only and not personalised advice — clinical outcomes are uncertain and past behaviour is not a reliable guide to future performance.
Cue Biopharma (CUE) Stock Forecast
Analyst price target, next 12 months
$35.00
+36.9% vs today's $25.57
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Cue Biopharma have a consensus 12-month target of $35.00, above the current price of $25.57.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 3 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying CUE Biopharma's stock with a target price of $35, indicating significant growth potential.
Financial Health
CUE Biopharma is generating promising revenue and cash flow, indicating strong operational performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial Readouts Matter
Clinical data are primary value drivers for Cue; positive or negative results can move the stock sharply, though outcomes are uncertain.
Binary Clinical Risk
As an early-stage biotech, Cue faces high binary risk around trial outcomes and regulatory decisions; potential reward comes with elevated volatility.
Partnerships & Funding
Licensing deals or successful financing can de‑risk development and extend runway, but funding needs may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
